Anterior resection is the most suitable surgical option for rectal tumors, except for those located in the lower rectum. When determining the appropriate surgery for colorectal cancer, it is crucial to consider the location of the tumor, its grade, and the feasibility of the operation. In the case of a tumor located just below the rectosigmoid junction, an anterior resection or abdominoperineal excision of the rectum are the two possible options. However, since the tumor is not invading the pelvic floor, anal canal, or anal sphincter, an anterior resection is the more appropriate choice. This procedure involves resection followed by anastomosis, with the creation of a temporary defunctioning ileostomy that can later be reversed to allow the bowel to heal. Abdominoperineal excision of the rectum is not suitable in this case, as it would require a lifelong stoma. Hartmann’s procedure is also not appropriate, as it is typically performed in emergency situations such as bowel perforation or obstruction. Similarly, left hemicolectomy is not suitable for this tumor, as it is located in the upper rectum.

Colorectal cancer is typically diagnosed through CT scans and colonoscopies or CT colonography. Patients with tumors below the peritoneal reflection should also undergo MRI to evaluate their mesorectum. Once staging is complete, a treatment plan is formulated by a dedicated colorectal MDT meeting.

For colon cancer, surgery is the primary treatment option, with resectional surgery being the only cure. The procedure is tailored to the patient and tumor location, with lymphatic chains being resected based on arterial supply. Anastomosis is the preferred method of restoring continuity, but in some cases, an end stoma may be necessary. Chemotherapy is often offered to patients with risk factors for disease recurrence.

Rectal cancer management differs from colon cancer due to the rectum’s anatomical location. Tumors can be surgically resected with either an anterior resection or an abdomino-perineal excision of rectum (APER). A meticulous dissection of the mesorectal fat and lymph nodes is integral to the procedure. Neoadjuvant radiotherapy is often offered to patients prior to resectional surgery, and those with obstructing rectal cancer should have a defunctioning loop colostomy.

Segmental resections based on blood supply and lymphatic drainage are the primary operations for cancer. The type of resection and anastomosis depend on the site of cancer. In emergency situations where the bowel has perforated, an end colostomy is often safer. Left-sided resections are more risky, but ileo-colic anastomoses are relatively safe even in the emergency setting and do not need to be defunctioned.

H. pylori Testing and Treatment Guidelines

To ensure accurate diagnosis and appropriate treatment for H. pylori infection, it is recommended that adults with dyspepsia or reflux symptoms undergo a 2-week washout period before testing for H. pylori if they are receiving PPI therapy. This applies to both the carbon-13-labelled urea breath test (UBT) and stool antigen test (SAT). Testing should not be performed within two weeks of PPI use, as this can lead to false negatives.

Patients with dyspepsia should be offered H. pylori ‘test and treat’ using a UBT, SAT, or laboratory-based serology. Office-based serological tests should not be used due to their inadequate performance. Retesting for eradication should be performed using a UBT, as there is insufficient evidence to recommend the SAT for this purpose.

First-line treatment for H. pylori eradication involves a 7-day, twice-daily course of a PPI, amoxicillin, and either clarithromycin or metronidazole. Multiple regimens are available, and local protocols should be consulted.

Guidelines for Accurate H. pylori Testing and Treatment

To undergo a urea breath test, one must not have taken antibiotics within the last four weeks and must not have taken any antisecretory drugs, such as PPI, within the last two weeks.

Tests for Helicobacter pylori

There are several tests available to diagnose Helicobacter pylori infection. One of the most common tests is the urea breath test, where patients consume a drink containing carbon isotope 13 (13C) enriched urea. The urea is broken down by H. pylori urease, and after 30 minutes, the patient exhales into a glass tube. Mass spectrometry analysis calculates the amount of 13C CO2, which indicates the presence of H. pylori. However, this test should not be performed within four weeks of treatment with an antibacterial or within two weeks of an antisecretory drug.

Another test is the rapid urease test, also known as the CLO test. This involves mixing a biopsy sample with urea and a pH indicator. If there is a color change, it indicates the presence of H. pylori urease activity. Serum antibody tests can also be used, but they remain positive even after eradication. Culture of gastric biopsy can provide information on antibiotic sensitivity, while histological evaluation alone can be done through gastric biopsy. Lastly, the stool antigen test has a sensitivity of 90% and specificity of 95%.

Overall, these tests have varying levels of sensitivity and specificity, and the choice of test depends on the patient’s clinical presentation and the availability of resources.

The patient’s symptoms of dull, central abdominal pain that worsens after meals and radiates to the back, along with a history of regular alcohol consumption, suggest a diagnosis of chronic pancreatitis. Imaging studies, such as an abdominal X-ray or CT scan, may reveal pancreatic calcifications, which are a common finding in chronic pancreatitis. If imaging is inconclusive, a faecal elastase test may be used to assess pancreatic exocrine function. The presence of the football sign, air under the diaphragm, dilated loops of small bowel, or the Rigler sign on an abdominal X-ray would suggest other conditions such as gastrointestinal perforation or bowel obstruction, which do not fit the patient’s presentation.

The probable diagnosis in this case is spontaneous bacterial peritonitis, as indicated by the presence of fever and absence of diarrhoea. The patient’s history of chronic alcohol abuse and diffuse oedema also suggests liver failure, which increases the risk of developing spontaneous bacterial peritonitis.

Understanding Spontaneous Bacterial Peritonitis

Spontaneous bacterial peritonitis (SBP) is a type of peritonitis that typically affects individuals with ascites caused by liver cirrhosis. The condition is characterized by symptoms such as abdominal pain, fever, and ascites. Diagnosis is usually made through paracentesis, which involves analyzing the ascitic fluid for a neutrophil count of over 250 cells/ul. The most common organism found on ascitic fluid culture is E. coli.

Management of SBP typically involves the administration of intravenous cefotaxime. Antibiotic prophylaxis is also recommended for patients with ascites who have previously experienced an episode of SBP or have a fluid protein level of less than 15 g/l and a Child-Pugh score of at least 9 or hepatorenal syndrome. NICE recommends prophylactic oral ciprofloxacin or norfloxacin until the ascites has resolved.

Alcoholic liver disease is a significant predictor of poor prognosis in SBP. Understanding the symptoms, diagnosis, and management of SBP is crucial for healthcare professionals to provide appropriate care and improve patient outcomes.

When dealing with an emergency situation where a colonic tumour has caused perforation, it is riskier to perform a colon-colon anastomosis. This is because it could result in an anastomotic leak, which would release bowel contents into the abdomen. Therefore, it is safer to perform an end colostomy, which can be reversed at a later time. Ileostomy, both end and loop, is not suitable for this patient as the perforation is located in the distal colon. Ileocolic anastomoses are generally safe in emergency situations and do not require de-functioning. However, in this case, an ileocolic anastomosis would not be appropriate as the obstructing lesion is in the distal colon rather than the proximal colon.

Colorectal cancer is typically diagnosed through CT scans and colonoscopies or CT colonography. Patients with tumors below the peritoneal reflection should also undergo MRI to evaluate their mesorectum. Once staging is complete, a treatment plan is formulated by a dedicated colorectal MDT meeting.

For colon cancer, surgery is the primary treatment option, with resectional surgery being the only cure. The procedure is tailored to the patient and tumor location, with lymphatic chains being resected based on arterial supply. Anastomosis is the preferred method of restoring continuity, but in some cases, an end stoma may be necessary. Chemotherapy is often offered to patients with risk factors for disease recurrence.

Rectal cancer management differs from colon cancer due to the rectum’s anatomical location. Tumors can be surgically resected with either an anterior resection or an abdomino-perineal excision of rectum (APER). A meticulous dissection of the mesorectal fat and lymph nodes is integral to the procedure. Neoadjuvant radiotherapy is often offered to patients prior to resectional surgery, and those with obstructing rectal cancer should have a defunctioning loop colostomy.

Segmental resections based on blood supply and lymphatic drainage are the primary operations for cancer. The type of resection and anastomosis depend on the site of cancer. In emergency situations where the bowel has perforated, an end colostomy is often safer. Left-sided resections are more risky, but ileo-colic anastomoses are relatively safe even in the emergency setting and do not need to be defunctioned.

A temporary and disproportionate increase in blood urea can be caused by an upper gastrointestinal bleed, which can function as a source of protein.

Acute upper gastrointestinal bleeding is a common and significant medical issue that can be caused by various conditions, with oesophageal varices and peptic ulcer disease being the most common. The clinical features of this condition include haematemesis, melena, and a raised urea level due to the protein meal of the blood. The differential diagnosis for acute upper gastrointestinal bleeding includes oesophageal, gastric, and duodenal causes.

The management of acute upper gastrointestinal bleeding involves risk assessment using the Glasgow-Blatchford score, which helps clinicians decide whether patients can be managed as outpatients or not. Resuscitation is also necessary, including ABC, wide-bore intravenous access, and platelet transfusion if actively bleeding platelet count is less than 50 x 10*9/litre. Endoscopy should be offered immediately after resuscitation in patients with a severe bleed, and all patients should have endoscopy within 24 hours.

For non-variceal bleeding, proton pump inhibitors (PPIs) should not be given before endoscopy to patients with suspected non-variceal upper gastrointestinal bleeding. However, PPIs should be given to patients with non-variceal upper gastrointestinal bleeding and stigmata of recent haemorrhage shown at endoscopy. If further bleeding occurs, options include repeat endoscopy, interventional radiology, and surgery. For variceal bleeding, terlipressin and prophylactic antibiotics should be given to patients at presentation, and band ligation should be used for oesophageal varices and injections of N-butyl-2-cyanoacrylate for patients with gastric varices. Transjugular intrahepatic portosystemic shunts (TIPS) should be offered if bleeding from varices is not controlled with the above measures.

Managing Crohn’s Disease: Guidelines and Treatment Options

Crohn’s disease is a type of inflammatory bowel disease that can affect any part of the digestive tract. To manage this condition, the National Institute for Health and Care Excellence (NICE) has published guidelines that provide recommendations for inducing and maintaining remission, as well as treating complications. One of the most important steps in managing Crohn’s disease is to advise patients to quit smoking, as this can worsen the condition. Additionally, some medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and the combined oral contraceptive pill, may increase the risk of relapse, although the evidence is not conclusive.

To induce remission, glucocorticoids are often used, either orally, topically, or intravenously. Budesonide is an alternative for some patients. Enteral feeding with an elemental diet may also be used, especially in young children or when there are concerns about the side effects of steroids. Second-line treatments for inducing remission include 5-ASA drugs like mesalazine, as well as azathioprine or mercaptopurine, which may be used in combination with other medications. Methotrexate is another option. Infliximab is useful for refractory disease and fistulating Crohn’s, and patients may continue on azathioprine or methotrexate.

To maintain remission, stopping smoking is a priority, and azathioprine or mercaptopurine is used first-line. TPMT activity should be assessed before starting these medications. Methotrexate is used second-line. Surgery may be necessary for around 80% of patients with Crohn’s disease, depending on the location and severity of the disease. Complications of Crohn’s disease include small bowel cancer, colorectal cancer, and osteoporosis. Perianal fistulae and abscesses require specific treatments, such as oral metronidazole, anti-TNF agents like infliximab, or a draining seton. By following these guidelines and treatment options, patients with Crohn’s disease can better manage their condition and improve their quality of life.

Differential Diagnosis of Liver Disorders in Pregnancy

Intrahepatic cholestasis of pregnancy (ICP), hyperemesis gravidarum, cholecystitis, acute fatty liver of pregnancy (AFLP), and HELLP syndrome are all potential liver disorders that can occur during pregnancy.

ICP is the most common pregnancy-related liver disorder and is characterised by generalised itching, jaundice, and elevated total serum bile acid levels. Maternal outcomes are good, but fetal outcomes can be devastating.

Hyperemesis gravidarum is characterised by persistent nausea and vomiting associated with ketosis and weight loss. Elevated transaminase levels may occur, but significantly elevated liver enzymes would suggest an alternative aetiology.

Cholecystitis is inflammation of the gall bladder that occurs most commonly due to gallstones. The most common presenting symptom is upper abdominal pain, which localises to the right upper quadrant.

AFLP is characterised by microvesicular steatosis in the liver and can present with malaise, nausea and vomiting, right upper quadrant and epigastric pain, and acute renal failure. Both AST and ALT levels can be elevated, and hypoglycaemia is common.

HELLP syndrome is a life-threatening condition that can potentially complicate pregnancy and is characterised by haemolysis, elevated liver enzyme levels, and low platelet levels. Symptoms are non-specific and include malaise, nausea and vomiting, and weight gain. A normal platelet count and no evidence of haemolysis are not consistent with a diagnosis of HELLP syndrome.

Early recognition, treatment, and timely delivery are imperative for all of these liver disorders in pregnancy.

The recommended treatment for ascites in this patient with liver cirrhosis is spironolactone. This medication is an aldosterone antagonist that helps counteract the fluid overload caused by secondary hyperaldosteronism in patients with hepatic cirrhosis. Azathioprine is not appropriate for this patient as it is used to treat autoimmune hepatitis. Ciprofloxacin may be prescribed for spontaneous ascites, but only if the ascitic protein is 15 g/litre or less, which is not the case for this patient. Prednisolone is used for acute liver failure, which is not the diagnosis for this patient with chronic liver disease.

Spironolactone is a medication that works as an aldosterone antagonist in the cortical collecting duct. It is used to treat various conditions such as ascites, hypertension, heart failure, nephrotic syndrome, and Conn’s syndrome. In patients with cirrhosis, spironolactone is often prescribed in relatively large doses of 100 or 200mg to counteract secondary hyperaldosteronism. It is also used as a NICE ‘step 4’ treatment for hypertension. However, it is important to note that spironolactone can cause hyperkalaemia and gynaecomastia, although the latter is less common with eplerenone.

One study, known as RALES, found that low dose spironolactone can reduce all-cause mortality in patients with NYHA III + IV heart failure who are already taking an ACE inhibitor. It is important to consult with a healthcare professional before taking spironolactone to determine if it is the right medication for your specific condition and to monitor for any potential adverse effects.

It is not recommended to use faecal occult blood testing for colorectal cancer screening in symptomatic patients who are under the age of 60. This woman is displaying symptoms of irritable bowel syndrome and has normal blood results, without any red flag symptoms. Repeating the full blood count is unlikely to provide any additional information. The use of steroids and azathioprine is not appropriate for treating irritable bowel syndrome, as they are typically used for ulcerative colitis, which is not likely in this case.

Colorectal Cancer Screening: Faecal Immunochemical Test (FIT)

Colorectal cancer is often developed from adenomatous polyps. Screening for this type of cancer has been proven to reduce mortality by 16%. The NHS offers a home-based screening programme called Faecal Immunochemical Test (FIT) to older adults. A one-off flexible sigmoidoscopy was trialled in England for people aged 55 years, but it was abandoned in 2021 due to the inability to recruit enough clinical endoscopists, which was exacerbated by the COVID-19 pandemic. The trial, partly funded by Cancer Research UK, showed promising early results, and it remains to be seen whether flexible sigmoidoscopy will be used as part of a future bowel screening programme.

Faecal Immunochemical Test (FIT) Screening:
The NHS now has a national screening programme that offers screening every two years to all men and women aged 60 to 74 years in England and 50 to 74 years in Scotland. Patients aged over 74 years may request screening. Eligible patients are sent FIT tests through the post. FIT is a type of faecal occult blood (FOB) test that uses antibodies that specifically recognise human haemoglobin (Hb). It is used to detect and quantify the amount of human blood in a single stool sample. FIT has advantages over conventional FOB tests because it only detects human haemoglobin, as opposed to animal haemoglobin ingested through diet. Only one faecal sample is needed compared to the 2-3 for conventional FOB tests. While a numerical value is generated, this is not reported to the patient or GP. Instead, they will be informed if the test is normal or abnormal. Patients with abnormal results are offered a colonoscopy. At colonoscopy, approximately 5 out of 10 patients will have a normal exam, 4 out of 10 patients will be found to have polyps that may be removed due to their premalignant potential, and 1 out of 10 patients will be found to have cancer.

Pancreatic cancer is the correct answer for this question, as indicated by Courvoisier’s sign. This sign suggests that a painless, enlarged gallbladder and mild jaundice are unlikely to be caused by gallstones, but rather by a malignancy of the pancreas or biliary tree. While alcoholic hepatitis and primary biliary cirrhosis are possible differentials, the presence of a painless, enlarged gallbladder makes them less likely. Paracetamol overdose is not a likely cause, as it would not result in a painless, palpable gallbladder and jaundice is not typically associated with this type of overdose.

Understanding Pancreatic Cancer: Risk Factors, Symptoms, and Management

Pancreatic cancer is a type of cancer that is often diagnosed late due to its non-specific symptoms. Adenocarcinomas, which occur at the head of the pancreas, make up over 80% of pancreatic tumors. Risk factors for pancreatic cancer include increasing age, smoking, diabetes, chronic pancreatitis, hereditary non-polyposis colorectal carcinoma, and genetic mutations such as BRCA2 and KRAS.

Symptoms of pancreatic cancer can include painless jaundice, pale stools, dark urine, pruritus, anorexia, weight loss, epigastric pain, loss of exocrine and endocrine function, and atypical back pain. Migratory thrombophlebitis, also known as Trousseau sign, is more common in pancreatic cancer than in other cancers.

Diagnosis of pancreatic cancer can be made through ultrasound or high-resolution CT scanning, which may show the double duct sign – simultaneous dilatation of the common bile and pancreatic ducts. However, less than 20% of patients are suitable for surgery at diagnosis. A Whipple’s resection, or pancreaticoduodenectomy, may be performed for resectable lesions in the head of the pancreas. Adjuvant chemotherapy is usually given following surgery, and ERCP with stenting may be used for palliation.

In summary, pancreatic cancer is a serious disease with non-specific symptoms that can be difficult to diagnose. Understanding the risk factors and symptoms can help with early detection and management.

Scleroderma (systemic sclerosis) frequently leads to malabsorption syndrome, which is characterized by reduced absorption of certain vitamins (B12, folate), nutrients (iron), and protein (low albumin) as indicated by blood tests.

Understanding Malabsorption: Causes and Symptoms

Malabsorption is a condition that is characterized by diarrhea, steatorrhea, and weight loss. It occurs when the body is unable to absorb nutrients from the food that is consumed. The causes of malabsorption can be broadly divided into three categories: intestinal, pancreatic, and biliary. Intestinal causes include conditions such as coeliac disease, Crohn’s disease, tropical sprue, Whipple’s disease, Giardiasis, and brush border enzyme deficiencies. Pancreatic causes include chronic pancreatitis, cystic fibrosis, and pancreatic cancer. Biliary causes include biliary obstruction and primary biliary cirrhosis. Other causes of malabsorption include bacterial overgrowth, short bowel syndrome, and lymphoma.

Elevated serum amylase levels are not always indicative of acute pancreatitis, as they can also be seen in cases of small bowel obstruction. In this scenario, the patient is experiencing abdominal pain, vomiting, and a lack of bowel movements or gas, which are all typical symptoms of small bowel obstruction. The fact that the patient has a history of abdominal surgery further supports this diagnosis, despite the misleading blood test results. Acute cholecystitis, on the other hand, presents with different symptoms such as fever, right upper quadrant pain, and systemic distress, and does not typically cause elevated amylase levels. Acute pancreatitis may also be considered as a differential diagnosis, but it is not associated with a lack of bowel movements or gas, and previous bowel surgery is not a risk factor. Ascending cholangitis and large bowel obstruction can also be ruled out based on the patient’s symptoms and test results.

Small bowel obstruction occurs when the small intestines are blocked, preventing the passage of food, fluids, and gas. The most common cause of this condition is adhesions, which can develop after previous surgeries, followed by hernias. Symptoms of small bowel obstruction include diffuse, central abdominal pain, nausea and vomiting (often bilious), constipation, and abdominal distension. Tinkling bowel sounds may also be present in early stages of obstruction. Abdominal x-ray is typically the first-line imaging for suspected small bowel obstruction, showing distended small bowel loops with fluid levels. CT is more sensitive and considered the definitive investigation, particularly in early obstruction. Management involves initial steps such as NBM, IV fluids, and nasogastric tube with free drainage. Some patients may respond to conservative management, but others may require surgery.

Tests for Helicobacter pylori

There are several tests available to diagnose Helicobacter pylori infection. One of the most common tests is the urea breath test, where patients consume a drink containing carbon isotope 13 (13C) enriched urea. The urea is broken down by H. pylori urease, and after 30 minutes, the patient exhales into a glass tube. Mass spectrometry analysis calculates the amount of 13C CO2, which indicates the presence of H. pylori. However, this test should not be performed within four weeks of treatment with an antibacterial or within two weeks of an antisecretory drug.

Another test is the rapid urease test, also known as the CLO test. This involves mixing a biopsy sample with urea and a pH indicator. If there is a color change, it indicates the presence of H. pylori urease activity. Serum antibody tests can also be used, but they remain positive even after eradication. Culture of gastric biopsy can provide information on antibiotic sensitivity, while histological evaluation alone can be done through gastric biopsy. Lastly, the stool antigen test has a sensitivity of 90% and specificity of 95%.

Overall, these tests have varying levels of sensitivity and specificity, and the choice of test depends on the patient’s clinical presentation and the availability of resources.

Primary biliary cholangitis is a chronic liver disease that primarily affects middle-aged women. It is characterized by the destruction of small bile ducts in the liver, leading to cholestasis and liver damage. The disease is diagnosed through blood tests that measure levels of specific antibodies and liver enzymes, which are highly specific to the condition. Ursodeoxycholic acid is the preferred treatment for slowing disease progression and improving symptoms, while cholestyramine can be used to alleviate itching but does not affect disease progression. In cases of decompensated liver disease, such as when bilirubin levels exceed 100, liver transplantation may be an option. Although recurrence in the graft can occur, it is typically not a significant issue. While fat-soluble vitamins can be supplemented, they are not a primary treatment option.

Primary Biliary Cholangitis: A Chronic Liver Disorder

Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a chronic liver disorder that is commonly observed in middle-aged women. The exact cause of this condition is not yet fully understood, but it is believed to be an autoimmune disease. The disease is characterized by the progressive damage of interlobular bile ducts due to chronic inflammation, leading to cholestasis and eventually cirrhosis. The most common symptom of primary biliary cholangitis is itching in middle-aged women.

This condition is often associated with other autoimmune diseases such as Sjogren’s syndrome, rheumatoid arthritis, systemic sclerosis, and thyroid disease. Early symptoms of primary biliary cholangitis may be asymptomatic or may include fatigue, pruritus, and cholestatic jaundice. Late symptoms may progress to liver failure. Diagnosis of primary biliary cholangitis involves immunology tests such as anti-mitochondrial antibodies (AMA) M2 subtype and smooth muscle antibodies, as well as imaging tests to exclude an extrahepatic biliary obstruction.

The first-line treatment for primary biliary cholangitis is ursodeoxycholic acid, which slows down the progression of the disease and improves symptoms. Cholestyramine is used to alleviate pruritus, and fat-soluble vitamin supplementation is recommended. In severe cases, liver transplantation may be necessary, especially if bilirubin levels exceed 100. However, recurrence in the graft can occur, but it is not usually a problem. Complications of primary biliary cholangitis include cirrhosis, portal hypertension, ascites, variceal hemorrhage, osteomalacia, osteoporosis, and an increased risk of hepatocellular carcinoma.

Diagnosis and Investigation of Coeliac Disease

Coeliac disease is a possible diagnosis in patients presenting with chronic diarrhoea and steatorrhoea. The initial investigation of choice is the anti-tissue transglutaminase (anti-TTG) test, which has a sensitivity of over 96%. However, it is important to check immunoglobulin A (IgA) levels concurrently, as anti-TTG is an IgA antibody and may not be raised in the presence of IgA deficiency.

The treatment of choice for coeliac disease is a lifelong gluten-free diet, avoiding gluten-containing foods such as wheat, barley, rye, and oats. Patients with coeliac disease are at increased risk of small bowel lymphoma and oesophageal carcinoma over the long term.

While faecal fat estimation may be useful in estimating steatorrhoea, small bowel biopsy is the gold standard investigation for coeliac disease. However, this would not be the initial investigation of choice as it is invasive. An anti-TTG test is more sensitive and specific than an anti-gliadin test in untreated coeliac disease. Magnesium (Mg2+) levels may be abnormal in coeliac disease, but this would not be diagnostic and therefore not the first investigation of choice.

In summary, the diagnosis of coeliac disease requires a combination of clinical presentation, laboratory investigations, and small bowel biopsy if necessary. The anti-TTG test is the initial investigation of choice, and a gluten-free diet is the treatment of choice.

Investigating Coeliac Disease

Coeliac disease is a condition caused by sensitivity to gluten, which can lead to villous atrophy and malabsorption. It is often associated with other conditions such as dermatitis herpetiformis and autoimmune disorders. Diagnosis of coeliac disease is made through a combination of serology and endoscopic intestinal biopsy. The gold standard for diagnosis is the biopsy, which should be performed in all patients with suspected coeliac disease to confirm or exclude the diagnosis. The biopsy traditionally takes place in the duodenum, but jejunal biopsies are also sometimes performed. Findings supportive of coeliac disease include villous atrophy, crypt hyperplasia, an increase in intraepithelial lymphocytes, and lamina propria infiltration with lymphocytes. Serology tests for coeliac disease include tissue transglutaminase antibodies and endomyseal antibodies, while anti-gliadin antibodies are not recommended. Patients who are already on a gluten-free diet should reintroduce gluten for at least six weeks prior to testing. Rectal gluten challenge is not widely used. A gluten-free diet can reverse villous atrophy and immunology in patients with coeliac disease.

Obstetric cholestasis, also known as intrahepatic cholestasis of pregnancy, is a condition that occurs when the flow of bile is impaired, resulting in a buildup of bile salts in the skin and placenta. The cause of this condition is believed to be a combination of hormonal, genetic, and environmental factors. While the pruritic symptoms can be distressing for the mother, the buildup of bile salts can also harm the fetus. The fetus’s immature liver may struggle to break down the excessive levels of bile salts, and the vasoconstricting effect of bile salts on human placental chorionic veins may lead to sudden asphyxial events in the fetus, resulting in anoxia and death.

Intrahepatic Cholestasis of Pregnancy: Symptoms and Management

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, close monitoring and management are necessary for women who have experienced this condition in the past.

Referral for Investigation of Colorectal Cancer with a 2-Week Wait

According to the National Institute for Health and Care Excellence (NICE) guidelines, patients aged 40 or over who present with unexplained weight loss and abdominal pain should be referred for investigation of colorectal cancer with a 2-week wait. Other criteria for a 2-week wait referral include patients with unexplained rectal bleeding, iron-deficiency anaemia, change in bowel habit, positive faecal occult blood tests, rectal or abdominal mass, unexplained anal mass or anal ulceration, and patients under 50 years with rectal bleeding and any of the following unexplained symptoms or findings: abdominal pain, change in bowel habit, weight loss or iron-deficiency anaemia.

Doing nothing and just following up with the patient, prescribing analgesia and following up in one month, referring the patient routinely, or taking urgent bloods and following up in two weeks would not be appropriate in the presence of red-flag symptoms and can create a serious delay in diagnosis and treatment. Therefore, referral for investigation of colorectal cancer with a 2-week wait is the recommended course of action. However, taking urgent bloods and following up the patient in two weeks can still be done while the patient is waiting for the referral appointment.